BridgeMD
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
EU CTIS ID: 2024-514081-40-00
What this study is testing
To demonstrate that orforglipron is superior to placebo for achieving BMI (Body Mass Index) reduction
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Have been diagnosed with obesity or overweight with at least one weight-related comorbidity (abnormal lipids, high blood pressure, fatty liver disease, sleep apnea, prediabetes, or type 2 diabetes)
- 2. Have not been able to lose weight with healthy diet and physical activity
You likely can't join if
- 1. Be prepubertal (have not started puberty)
- 2. Have lost more than 5 kg (11 pounds) in the 90 days before screening
- 3. Have type 1 diabetes
- 4. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2
- 5. Have had or plan to have a weight loss surgery during the study
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Israel
- United Kingdom
- Mexico
- China
- Brazil
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Israel; United Kingdom; Mexico; China; Brazil and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.